438585-72-9Relevant academic research and scientific papers
MRGPRX2 ANTAGONISTS AND USES THEREOF
-
Paragraph 00215-00216, (2021/05/15)
The present disclosure is directed to use of MrgprX2 antagonists in the treatment of inflammatory disorders, e.g., inflammatory disorders of the skin. This invention is also directed to pharmaceutical compositions comprising a MrgprX2 antagonist and a pharmaceutically or orally acceptable carrier for administration.
Investigating Structural Requirements for the Antiproliferative Activity of Biphenyl Nicotinamides
Majellaro, Maria,Stefanachi, Angela,Tardia, Piero,Vicenti, Chiara,Boccarelli, Angelina,Pannunzio, Alessandra,Campanella, Federica,Coluccia, Mauro,Denora, Nunzio,Leonetti, Francesco,de Candia, Modesto,Altomare, Cosimo Damiano,Cellamare, Saverio
, p. 1380 - 1389 (2017/09/01)
A number of trimethoxybenzoic acid anilides, previously studied as permeability glycoprotein (P-gp) modulators, were screened with the aim of identifying new anticancer agents. One of these compounds, which showed antiproliferative activity against resist
Trimethoxybenzanilide-based P-glycoprotein modulators: An interesting case of lipophilicity tuning by intramolecular hydrogen bonding
Tardia, Piero,Stefanachi, Angela,Niso, Mauro,Stolfa, Diana Antonella,Mangiatordi, Giuseppe Felice,Alberga, Domenico,Nicolotti, Orazio,Lattanzi, Gianluca,Carotti, Angelo,Leonetti, Francesco,Perrone, Roberto,Berardi, Francesco,Azzariti, Amalia,Colabufo, Nicola Antonio,Cellamare, Saverio
, p. 6403 - 6418 (2014/10/16)
One of the principal reasons for the chemotherapy failure is the overexpression of drug efflux pumps, ABCB1 (also known as MDR1 or P-gp) and ABCC1 (also known as MRP1), whose inhibition remains a priority to circumvent drug resistance. We have recently sh
